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Sunnua" Regional chemotherapy. delivered via the hepatic artery. may significantly increase tumour re-
sponse rates in patients with colorectal liver metastases. However, survival is limited by extrahepatic disease
progression. We have developed a novel therapeutic approach for patients with metastases confined to the
liver. In order to achieve high local response rates and also inhibit extrahepatic progression. 5-fluorouracil
(5-FU) was infused intra-arterially at a dose previously calculated to achieve both high-dose regional therapy
and adequate systemic levels. To enhance efficacy further, 5-FU was combined with high-dose systemic folinic
acid (FA). Thirty-one patients were evaluated in a phase II study. 5-FU (1.5 g m2) was infused via a surgically
implanted hepatic artery catheter over a 24 h period: FA (total 400 mg m-2) was infused intravenously during
the initial and final 2 h. Treatments were given weekly for cycles of 6 weeks' duration. To date, median
duration of treatment is 6 months and the median follow-up period is 17 months. The overall response rate
was 48% with two complete and 13 partial responses. Predicted median time to progression is 8 months. The
site of first progression was hepatic in 10 (42%) and extrahepatic in 14 (58%) patients. Seven patients
developed local complications; one required emergency surgery. Side-effects were limited to grade 3 toxicity
(four patients) or less. Predicted median survival is 19 months. This approach, which is associated with a high
response rate and low systemic toxicity. warrants further evaluation. A phase III study is planned.
The outlook for patients with colorectal liver metastases is
poor. Untreated. median survival is in the region of 3-6
months (Wood et al.. 1976: Fortner et al.. 1984). While
hepatic resection offers a hope of cure for those with limited
disease confined to one lobe, less than 5% of patients are
suitable for such treatment. and in these 5 year survival is
approximately 30% (Cady & Stone. 1991). Thus the vast
majority of patients remain incurable.
Until recently the results of systemic chemotherapy have
been disappointing. 5-Fluorouracil (5-FU) and its analogue
5-fluoro-2-deoxyuridine (FUDR) remain the most active
agents for colorectal metastases. but response rates to these
alone are less than 20% (Kemeny & Seiter. 1991). Most
cytotoxic drugs have steep dose-response curves such that
increased response rates are achieved with higher dose
regimens. Attempts to increase systemic doses of 5-FU. how-
ever. have led to unacceptable toxicity.
Regional chemotherapy is an approach which can over-
come this problem. Intrahepatic arterial (IHA) admini-
stration of cytotoxics has been shown to increase tumour
response rates while at the same time systemic exposure and
therefore toxicity are reduced (Kemeny et al., 1987; Pinedo.
1988). FUDR. which is almost totally metabolised on first
pass through the liver, has been widely used for the regional
treatment of liver metastases. However, despite high response
rates with this drug. it is apparent that survival is limited
because patients develop extrahepatic metastases (O'Connell.
1992).
Regional administration of 5-FU. which is incompletely
extracted on first hepatic passage. may be an appropnrate
alternative. Not only can this achieve high tumour drug
levels. but also the systemic 'spill-over' could inhibit the
growth of extrahepatic metastases. Furthermore, the
therapeutic efficacy of 5-FU may be improved both by ad-
ministering it as a prolonged infusion and by including
biochemical modulators such as folinic acid (FA) in the
regimen (Kerr. 1989; Lokich et al.. 1989).
In this study we have combined these factors to develop a
novel therapeutic approach. Based on pharmacokinetic and
phase I studies (Goldberg et al.. 1990; Anderson et al..
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1992a) we initiated a phase II study using high-dose IHA
5-FU so that 'spill-over' into the systemic circulation occur-
red. To enhance efficacy further. we adopted a schedule using
prolonged infusions modulated by high-dose systemic folinic
acid. Our aims were not only to maximise tumour response
rates but also to delay extrahepatic progression in an attempt
to prolong survival.
Patients and methods
From 1 March 1990 to 31 March 1993. 59 patients with
colorectal liver metastases were considered for possible in-
clusion in the study. which had previously been approved by
the local ethical committee. Five of these patients had a
WHO performance >2 and were not investigated further.
The remaining patients underwent CT scanning of abdomen
and pelvis and either thoracic computerised tomography
(CT) or chest radiography to exclude extrahepatic disease. If
there was no evidence of tumour outside the liver, hepatic
arteriography was performed to establish the hepatic arterial
anatomy. Ultrasound-guided liver biopsy was carried out if
histological proof of metastases had not previously been
obtained. On the basis of these investigations a further 23
patients were excluded from the study. Of these. 19 had extra-
hepatic metastases. one had a solitary metastasis which was
formally resected. one did not have measurable tumour, one
was unable to attend according to the study schedule and
one declined treatment.
Thirty-one patients [nine female, 22 male. median age 59
years (range 37-77)] were therefore included. Multiple meta-
stases were detected at the time of primary surgery in 24
patients. Three patients had undergone either wedge resection
elsewhere (n = 2) or formal hepatic resection (n = 1) for
apparently solitary tumours and were included following
tumour recurrence. The remaining four patients had meta-
stases diagnosed at follow-up (range 5-15 months post resec-
tion of the primary tumour). Six patients had between 25%
and 50% of their livers replaced by tumour (assessed by CT
image analysis), while the others had less than 25% hepatic
replacement. The median number of metastases was 5 (range
1-30). The patient with a solitary tumour had a catheter
placed at the time of primary surgery with a view to treating
with regional chemotherapy and hepatic resection at a later
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date if no further metastases developed. Five patients had
previously received chemotherapy for their metastases. Of
these, three were treated with intravenous 5-FU and folinic
acid, one had intra-arterial mitomycin C and lipiodol and
one had targeted embolisation of tumour with yttrium-90
loaded glass microspheres.
Totally implantable silicone arterial catheters (Infusaid
arterial catheter, Shiley Infusaid, Norwood, MA, USA, and
Jet Port Plus Hepatic catheter, Meadox UK, Caddington,
Beds, UK) were inserted at laparotomy. The median interval
between diagnosis of hepatic tumour and catheterisation was
3 months (range 0-14 months). In patients with normal
anatomy (n = 21), the catheters were inserted retrogradely
into the gastroduodenal artery and positioned so that the
catheter tip lay at its origin (Watkins et al., 1970). In patients
with variant anatomy, perfusion was achieved using a variety
of techniques. These included ligation of aberrant vessels, the
use of end-to-side saphenous vein grafts as conduits for
catheter insertion (Goldberg et al., 1989) and retrograde
cannulation of the splenic artery. Complete perfusion of the
liver was confirmed in all patients by per-catheter injection of
methylene blue dye. To prevent unwanted perfusion of other
viscera any vessels supplying the stomach, duodenum or
pancreas which took origin distal to the site of catheterisa-
tion were ligated. Cholecystectomy was performed to prevent
chemical cholecystitis. The catheters were connected to access
ports placed subcutaneously over the costal margin through a
separate incision. One week post operatively the catheters
were flushed with heparinised saline (2,000 units in 5 ml)
using a Huber needle inserted under local anaesthetic. Fol-
lowing discharge, arrangements were made to commence
treatment following a short period of convalescence (usually
2 weeks).
Chemotherapy was given according to the schedule previ-
ously determined by the phase I study (Anderson et al.,
1992a). Intra-arterial 5-FU (1.5 gm-) was administered as
a weekly 24 h infusion with intravenous folinic acid
(200 mgm2) given as infusions over the first 2 and last 2 h
of the 24 h period. This dose was chosen in order to maxi-
mise the modulation of thymidylate synthetase inhibition by
5-FU (Anderson et al., 1992b). Chemotherapy was com-
menced between 1 and 6 weeks (median 3 weeks) following
insertion of catheter. All patients were given dexamethasone
8 mg i.v. at the start of each infusion as prophylaxis against
nausea and vomiting. Additional antiemetics and antidiar-
rhoeal drugs were given if required. Oral ranitidine
150 mg b.d. was prescribed routinely to protect against peptic
ulceration. Infusions were given weekly for 6 weeks followed
by a 2 week rest prior to the start ofthe next treatment cycle.
Dose reduction of 5-FU by 25% increments was performed
for patients with symptoms of systemic toxicity not relieved
by standard antiemetics or antidiarrhoeal agents.
Initially patients were admitted for treatment but latterly
the infusions of 5-FU were administered using a portable
pump (Walkmed 300, Medfusion, Duluth, USA). With this
the patients attended hospital on an out-patient basis for
commencement of their infusions and again, the following
day, for the final folinic acid infusion and subsequent discon-
nection.
Table I Response rates after first cycle (2 months)
Complete Partial Static Progressive
response response disease disease
Response I 10 16 4
Table II Worst systemic toxicity
WHO toxicity grade
Symptom 0 1 2 3 4
Nausea/vomiting 16 6 6 3 -
Diarrhoea 25 2 3 1
Mucositis 29 1 1 - -
Response to treatment was assessed at the end of each
cycle of six treatments by CT scanning. Treatment was dis-
continued when there was objective evidence of disease pro-
gression, or when significant systemic toxicity occurred which
did not respond to dose reduction. Patients progressing on
therapy were referred for further treatment using phase I
study drugs. Those whose catheters became occluded or who
developed unacceptable local side-effects (e.g. peptic ulcera-
tion) continued with intravenous 5-FU and folinic acid
(500-600mgm-2 5-FU, 400mgm-2 FA) according to the
same schedule. Tumour response and toxicity were defined
according to standard WHO criteria (Miller et al., 1981).
Resuks
Treatment
All 31 patients received at least one treatment cycle and are
therefore eligible for response and toxicity evaluation. At
present two patients are still receiving treatment according to
the study protocol. To date the median duration of therapy
is 6 months (range 2- 16 months) and the median cumulative
dose of 5-FU is 38.4 g (range 14.4-144 g). Median follow-up
is 17 months (range 3-36 months).
Response
Eleven (35%) patients showed a response to treatment at the
initial 2 month assessment; of these one had a complete
response (Table I). Delayed responses occurred in four
patients who initially had stable disease and subsequently
had partial responses after a mean duration of 6 months
(range 4-13 months). In addition, one patient who showed a
partial response after the initial assessment converted to a
complete response after 12 months of treatment. Thus 15 out
of 31 patients (48%) responded overall. The patients who
had complete responses remain disease free at 36 and 24
months. Three of the five patients who had previous intra-
arterial or systemic therapy had partial responses.
Toxicity
Systemic toxic effects occurred in 15 patients (Table II).
Nausea, vomiting and diarrhoea were the most frequent
symptoms. Two patients developed oral mucositis. Toxic
effects were generally mild, with no cases of grade 4 toxicity.
Myelosuppression and hand/foot syndrome were not en-
countered. In the majority of patients symptoms were
adequately controlled with standard antiemetics and antidiar-
rhoeal drugs. Four patients required dose reduction; three by
25% and one by 50%. Of these, two patients opted to
discontinue treatment at 4 and 8 months, one with grade 2
and the other with grade 3 vomiting.
Local toxicity, attributable to arterial perfusion, was seen
in four patients. Upper gastrointestinal haemorrhage from
duodenal ulceration of duodenitis occurred in three patients,
two of whom settled with conservative treatment. One
patient required an emergency Polya gastrectomy. One
patient had asymptomatic chemical hepatitis which resolved
on cessation of treatment. Two patients developed liver ab-
scesses. One grew a methicdllin-resistant Staphylococcus
aureus which responded to treatment with vancomycin and
percutaneous drainage, the other grew coliforms and re-
sponded to ciprofloxacin. One patient developed a retro-
peritoneal haematoma following catheter displacement, and
bleeding from the injection port due to coring of the septum
occurred in a further patient. To date, catheter occlusion has
occurred in 15 patients with a median time to failure of 12
months (range 3-18 months).
Progression
To date, 24 patients have progressed. Predicted median time
to progression is 8 months (Figure 1). The liver was the site
of initial progression in 10 (42%), whereas progression firstREGIONAL 5-FU FOLINIC ACID FOR COLORECTAL LIVER METASTASES 679
occurred in extrahepatic sites in the remaining
patients pulmonary and locoregional recurreni
with equal frequency (Table III).
Survival
To date, 20 patients have died, 18 of whom dies
disease. Two patients died without clinical or
evidence of disease progression, one from viral
and the other at home; post-mortem examinati
performed. Predicted median survival from t
catheter insertion is 19 months (Figure 2).
The biochemical modulation of 5-FU with folir
been an important recent advance in the system
of patients with widespread colorectal cancer (Ke
nine phase III studies which have compared sys
with 5-FU and folinic acid the overall response
combination is 23% compared with only 11 I
alone (Piedbois et al., 1992). However, adding
also increases toxicity (Rustum, 1989). For exca
study in which high-dose folinic acid (500 mg
was administered with 5-FU (0.6gm-2week-'),
27% incidence of life-threatening diarrhoea (Pe
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TableI Initial siteoftumourprogression inpatients w
disease (n = 24)
Liver 10
Lung 6
Locoregional 6
Bone 2
Total 24
14. In these 1987). Furthermore, increased response rates have not led to
ce occurred significantly improved survival (Piedbois el al., 1992).
For patients with metastases confined to the liver, targeting
cytotoxics by regional administration is an attractive concept
which may circumvent the restrictions of systemic chemo-
therapy. Based on a sound pharmacological rationale, this
d from their approach can produce high tumour response rates with
radiological minimal systemic toxicity. Three levels of targeting have been
pneumonia described (Widder et al., 1979). At the first level selective
ion was not delivery to the tumour-bearing organ is achieved. With
he time of second-level targeting, drug is directed to tumour rather than
to normal tissue within the organ. Third-level targeting
enhances uptake of drug by malignant cells. As hepatic
metastases derive their blood supply predominantly from the
hepatic artery (Breedis & Young, 1954), infusion of cyto-
toxics via the hepatic artery therefore achieves first- and, to a
nic acid has degree, second-level targeting. With this approach higher
ic treatment drug concentrations may be delivered to the tumour while
rr, 1989). In overall systemic exposure, and hence toxicity, may be
stemic 5-FU reduced. The reduction in systemic exposure is increased if
rate for the drugs which have a high first-pass hepatic extraction are
lo for 5-FU used.
folinic acid FUDR, which has a first-pass extraction of 94-99%, is
mple in one theoretically ideal for regional therapy (Ensminger et al.,
m 2week-) 1978). For this reason, and also because its high solubility
there was a makes it suitable for use with totally implantable infusion
-trelli et al., pumps, FUDR has been accepted as the drug of choice for
regional treatment of colorectal liver metastases. The re-
sponse rates reported with IHA FUDR are high, ranging
between 32% and 83% (Kemeny, 1992). Despite this, the
results of seven randomised studies comparing it with
systemic therapy are less encouraging. Only one of these, a
French consortium study, has shown significantly improved
survival with regional administration (Rougier et al., 1992),
but in this study half the patients in the control arm received
no treatment at all. Furthermore, while systemic side-effects
are not encountered with regional FUDR, hepatobiliary toxi-
city secondary to arterial infusion is a substantial problem. In
the French study chemical hepatitis or biliary sclerosis occur-
red in 65% of patients.
Because systemic drug levels are negligible with IHA
~3 -~-36 FUDR, poor survival is related to the rapid development of 30 3 extrahepatic metastases (O'Connell, 1992). A logical ap-
proach, therefore, is to combine regional with adjuvant
systemic treatment in order to inhibit extrahepatic progres-
sion. Safi et al. (1989) addressed this in a small randomised
on. Median study which compared patients receiving combined IHA and
systemic FUDR with a group who had IHA FUDR alone.
Extrahepatic recurrence was 61% in the 23 patients treated
with IHA FUDR alone compared with 33% in 21 patients
who received combined therapy. Disappointingly, there was
no difference in survival.
We have adopted an alternative approach. Because the
first-pass hepatic extraction of 5-FU is between 19% and
54% (Ensminger et al., 1978), intra-arterial administration of
5-FU is likely to produce not only high intrahepatic drug
levels but also significant systemic levels as a result of
unmetabolised drug spilling over from the liver into the
systemic circulation. By combining this with folinic acid and
using a prolonged infusional regimen, we aimed to maximise
30 36 local tumour response and simultaneously delay extrahepatic
progression. From our phase I study we found that the
1 maximum safe dose of IHA 5-FU given over 24 h with FA
400mgm-2 was 1.5gm-2week-'. At 2.0gm-2week-'
survival is grade 3 or 4 diarrhoea and/or vomiting occurred in half the patients. Although we have previously shown that there is
significant regional advantage in giving FA via the hepatic
ithprogressive artery, this was associated with arterial occlusion in some
patients (Anderson et al., 1992b). We therefore chose to
administer FA systemically.
These results suggest that this approach is effective. The
tumour response rate of 48% compares favourably with
those of the previous HAI FUDR phase III studies for
colorectal liver metastases (Kemeny, 1992). Systemic toxicity
in this study was mild, with no grade 4 and only four cases680 H.W. WARREN et al.
of grade 3 toxicity. This is similar, in both spectrum and
degree. to the toxicity encountered in studies of systemic
5-FU and folinic acid which utilised similar prolonged
infusional schedules (De Gramont et al.. 1988: Johnson et al..
1991). and therefore indicates that we were achieving equiva-
lent therapeutic systemic drug levels.
Biliary sclerosis, commonly seen with regional FUDR
infusion, was not seen, and only one patient had transient
biochemical evidence of hepatitis. However, other local com-
plications did occur. Despite prophylactic H,-blockers, upper
gastrointestinal haemorrhage occurred in three patients,
presumably as a result of misperfusion. Although this should
be minimised by careful ligation of any vessels arising from
the hepatic artery which supply stomach or duodenum, it is
recognised that collaterals may develop (Kemeny et al.,
1984). Early investigation of dyspeptic symptoms by endo-
scopy is therefore mandatory.
Hepatic abscess formation was another serious complica-
tion. In the patient infected with Gram-negative bacilli this
was associated with chronic suppuration at the subcutaneous
port site, while a hospital-acquired staphylococcal infection
occurred in the other. Despite this, both patients responded
to parenteral antibiotic therapy (although one required addi-
tional percutaneous drainage). One is still alive 21 months
post catheterisation while the other died at 20 months of
progressive liver disease.
The majority of patients who progressed did so at extra-
hepatic sites in the first instance, indicating that control of
local disease was superior to the inhibitory effect of the
systemic component. However, the median time to progres-
sion of 8 months suggests that disease progression was
delayed. The high response rate and relative lack of toxicity
suggest that this regimen warrants further evaluation. A
phase III study comparing systemic and regional 5-FU and
folinic acid regimens is now planned.
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